| Previous Close | 1.68 |
| Open | 1.66 |
| Bid | 1.30 x 1600 |
| Ask | 1.80 x 1500 |
| Day's Range | 1.63 - 1.68 |
| 52 Week Range | 1.56 - 10.90 |
| Volume | 146,292 |
| Avg. Volume | 360,640 |
| Market Cap | 4.86M |
| Beta | 4.66 |
| PE Ratio (TTM) | -0.40 |
| EPS (TTM) | -4.18 |
| Earnings Date | May 12, 2017 - May 15, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.00 |
- ACCESSWIREā¢3 days ago
Featured Company News - Soligenix Receives $2.5 million in Additional NIAID Funding to Advance Development of Heat Stable Ricin Vaccine
Research Desk Line-up: Cyclacel Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / August 16, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for ...
- Thomson Reuters StreetEventsā¢3 days ago
Edited Transcript of CYCC earnings conference call or presentation 9-Aug-17 8:30pm GMT
Q2 2017 Cyclacel Pharmaceuticals Inc Earnings Call
- GlobeNewswireā¢10 days ago
Cyclacel Pharmaceuticals Reports Second Quarter 2017 Financial ResultsĀ
BERKELEY HEIGHTS, N.J., Aug. 09, 2017-- Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop ...
